Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 28;15(19):4758.
doi: 10.3390/cancers15194758.

Trends in Outcome of Hematopoietic Stem Cell Transplantation: 5000 Transplantations and 30 Years of Single-Center Experience

Ludmila Stepanovna Zubarovskaya  1 , Ivan Sergeevich Moiseev  1 , Maria Dmidrievna Vladovskaya  1 , Natalia Borisovna Mikhailova  1 , Elena Vladislavovna Morozova  1 , Tatyana Alexandrovna Bykova  1 , Yulia Yurievna Vlasova  1 , Olesya Vladimirovna Paina  1 , Ilya Viktorovich Kazantsev  1 , Olga Alexandrovna Slesarchuk  1 , Anna Gennadyevna Smirnova  1 , Anna Alekseevna Osipova  1 , Liliya Vladimirovna Stelmakh  1 , Alexey Yurievich Polushin  1 , Oleg Valerievich Goloshchapov  1 , Maxim Pavlovich Bogomolny  1 , Maria Arkadievna Estrina  1 , Marina Olegovna Popova  1 , Maxim Anatolievich Kucher  1 , Alisa Georgievna Volkova  1 , Alexander Leonidovich Alyansky  1 , Dmitrii Eduardovich Pevtcov  1 , Natalia Evgenievna Ivanova  1 , Elena Vitalievna Babenko  1 , Nikolai Nikolaevich Mamaev  1 , Tatiana Leonidovna Gindina  1 , Alina Alexandrovna Vitrishchak  1 , Alexei Borisovich Chukhlovin  1 , Elena Vladimirovna Semenova  1 , Sergei Nicolaevich Bondarenko  1 , Alexander Dmitrievich Kulagin  1 , Boris Vladimirovich Afanasyev  1
Affiliations

Trends in Outcome of Hematopoietic Stem Cell Transplantation: 5000 Transplantations and 30 Years of Single-Center Experience

Ludmila Stepanovna Zubarovskaya et al. Cancers (Basel). .

Abstract

In this single-center analysis, we evaluated the trends in 5185 hematopoietic cell transplantations performed between 1990 and 2022. The study group comprised 3237 allogeneic (alloHCT) and 1948 autologous (autoHCT) hematopoietic cell transplantations. In the multivariate analysis, there was an improvement in event-free-survival (EFS) after autoHCT (HR 0.6, 95% CI 0.4-0.7, p < 0.0001) due to reduced cumulative incidence of relapse in the last five years (56% in 2010-2014 vs. 38% in 2015-2022). An improvement in EFS after alloHCT over time was observed (HR 0.33, 95% CI 0.23-0.48, p < 0.0001), which was due to reduced non-relapse mortality. No difference in cumulative relapse incidence was observed over the last decade for allografted patients. Survival after autoHCT improved in Hodgkin's disease (HR 0.1, 95% CI 0.1-0.3), multiple myeloma (HR 0.4, 95% CI 0.2-0.7) and solid tumors (HR 0.2, 95% CI 0.2-0.4), while after alloHCT, improvement was observed in acute myeloid leukemia (HR 0.3, 95% CI 0.1-0.5), acute lymphoblastic leukemia (HR 0.2, 95% CI 0.1-0.5), Hodgkin's disease (HR 0.1, 95% CI 0.0-0.4), non-Hodgkin's lymphomas and chronic lymphocytic leukemia (HR 0.2, 95% CI 0.0-0.6), inborn diseases (HR 0.2, 95% CI 0.2-0.4) and acquired aplastic anemia with matched related donors and matched unrelated donors (HR 0.3, 95% CI 0.2-0.8).

Keywords: allogeneic hematopoietic stem cell transplantation; autologous hematopoietic stem cell transplantation; survival over time; trends.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Number of hematopoietic stem cell transplantations at the RM Gorbacheva Research Institute by year of transplantation.
Figure 2
Figure 2
The number of hematopoietic stem cell transplantations at RM Gorbacheva Research Institute by year of transplantation Changes in the transplant program at RM Gorbacheva Research Institute over time. (A) The ratio of autoHCT and alloHCT. (B) Indications for autoHCT. (C) The ratio of donor types for alloHCT. (D) Indications for alloHCT.
Figure 3
Figure 3
The impact of year of transplant on overall survival. (A) Overall survival after autoHCT. (B) Overall survival after alloHCT.
Figure 4
Figure 4
Forest plot with results of multivariate analysis. (A) Influence of factors on overall survival after alloHCT. (B) Influence of factors on event-free survival after alloHCT. (C) Influence of factors on event-free survival after autoHCT.
Figure 5
Figure 5
Forest plot of hazard ratios for 5-year overall survival after alloHCT for selected diseases.
Figure 6
Figure 6
Forest plot of hazard ratios for 5-year overall survival after autoHCT for selected diseases.
See this image and copyright information in PMC

References

    1. Penack O., Peczynski C., Mohty M., Yakoub-Agha I., Styczynski J., Montoto S., Duarte R.F., Kröger N., Schoemans H., Koenecke C., et al. How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT. Blood Adv. 2020;4:6283–6290. doi: 10.1182/bloodadvances.2020003418. - DOI - PMC - PubMed
    1. Kanate A.S., Majhail N.S., Savani B.N., Bredeson C., Champlin R.E., Crawford S., Giralt S.A., LeMaistre C.F., Marks D.I., Omel J.L., et al. Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. Biol. Blood Marrow Transplant. 2020;26:1247–1256. doi: 10.1016/j.bbmt.2020.03.002. - DOI - PubMed
    1. Bazarbachi A., Boumendil A., Finel H., Khvedelidze I., Romejko-Jarosinska J., Tanase A., Akhtar S., Ben Othman T., Ma’koseh M., Afanasyev B., et al. The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years. Leukemia. 2022;36:1646–1653. doi: 10.1038/s41375-022-01563-8. Erratum in: Leukemia 2022, 36, 2150. - DOI - PubMed
    1. Hegerova L., Cao Q., Lazaryan A., McClune B.L., Weisdorf D.J., Brunstein C.G., Bachanova V. Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era. Bone Marrow Transplant. 2017;52:697–703. doi: 10.1038/bmt.2016.357. - DOI - PMC - PubMed
    1. Snowden J.A., Saccardi R., Orchard K., Ljungman P., Duarte R.F., Labopin M., McGrath E., Brook N., de Elvira C.R., Gordon D., et al. Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) Bone Marrow Transplant. 2020;55:681–694. doi: 10.1038/s41409-019-0718-7. Erratum in Bone Marrow Transplant. 2020, 55, 838–839. - DOI - PMC - PubMed

LinkOut - more resources